Clearside Biomedical's Third Quarter Financial Results Announcement
Clearside Biomedical, Inc. is thrilled to announce that it will report its third quarter financial results soon. This event is part of a crucial period for the company, which is dedicated to enhancing the delivery of therapies to the back of the eye, utilizing its innovative suprachoroidal space (SCS) technology.
Details of the Financial Results Event
The highly anticipated financial results will be shared on a Tuesday in mid-November after the financial markets close for the day. Following the release of these results, the management team will host a live webcast and conference call to provide insights and discuss the company's performance during the quarter. This call is particularly important for stakeholders looking to gauge the company’s progress and future plans.
How to Participate in the Webcast
For those interested in joining the conversation, the live and archived webcast will be accessible through the Clearside Biomedical website in the Investors section. Participants are encouraged to dial in promptly, as the company recommends joining about 15 minutes early to ensure connectivity.
About Clearside Biomedical, Inc.
Clearside Biomedical is pioneering a novel approach in the biopharmaceutical field with its SCS Microinjector technology. This method allows for an in-office, non-surgical procedure that enables the targeted delivery of therapies directly to the eye's macula, retina, or choroid, significantly improving patient outcomes for those afflicted with serious eye diseases. Through their extensive research and development, Clearside aims to enhance the quality of life for patients at risk of vision loss.
Innovative Treatment Pipeline
The company is actively developing its pipeline of small molecule product candidates, all of which are designed to be administered via the SCS Microinjector. Their leading program, CLS-AX (axitinib injectable suspension), aims to treat neovascular age-related macular degeneration (wet AMD). This program has progressed to a Phase 2b clinical trial stage, with plans for a comprehensive Phase 3 program underway.
Successful Product Launches
One of Clearside's significant achievements is the development and market approval of their first product, XIPERE (triamcinolone acetonide injectable suspension). This innovative product, specifically designed for suprachoroidal use, is currently available in the U.S. through a commercial partnership, further showcasing the company's commitment to advancing eye care.
Future Directions and Partnerships
Clearside Biomedical is continually expanding its reach by forming strategic partnerships with other firms focused on innovative ophthalmic therapeutic solutions. These collaborations not only broaden their capabilities but also enhance their ability to deliver effective treatments to patients worldwide.
Investor Relations Contact Information
For investor inquiries or further information regarding the upcoming financial results and corporate updates, interested parties may contact:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Frequently Asked Questions
When will Clearside Biomedical report its financial results?
Clearside Biomedical is set to report its third quarter financial results on a Tuesday in mid-November.
How can I access the financial results webcast?
The webcast can be accessed through the Clearside Biomedical website in the Investors section on the day of the results announcement.
What is the significance of the SCS Microinjector?
The SCS Microinjector enables a non-surgical approach to deliver therapies directly to the eye, improving treatment outcomes for patients with serious eye conditions.
What are the benefits of the CLS-AX program?
CLS-AX is being developed to treat wet AMD, and its progress to Phase 3 trials signifies its potential to address a major eye disease affecting many people.
Who should I contact for investor relations inquiries?
For investor relations questions, you can reach out to Jenny Kobin or Remy Bernarda at ir@clearsidebio.com or by calling (678) 430-8206.
